Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong(®)) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhouhong, Chen, Xuefeng, Dong, Guanping, Lou, Yin, Zhang, Jianping, Cheng, Xinran, Pan, Jiayan, Liao, Wei, Wu, Jinzhun, Huang, Xiaodong, Jin, Xianjiang, Liu, Deyun, Zeng, Ting, Zhu, Shunye, Dong, Qin, Luo, Xiaoming, Lan, Dan, Cao, Lizhi, Zhang, Xingxing, Liu, Jing, Dai, Mingjuan, Zhang, Manyan, Liu, Li, Dong, Junhua, Zhao, Dongmei, Ni, Shaoqing, Fu, Junfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402941/
https://www.ncbi.nlm.nih.gov/pubmed/36034802
http://dx.doi.org/10.3389/fphar.2022.955809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402941/
https://www.ncbi.nlm.nih.gov/pubmed/36034802
http://dx.doi.org/10.3389/fphar.2022.955809

Ejemplares similares